A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

NCT04132570 PHASE4 COMPLETED

The primary objective of this study is to assess the effectiveness of intranasal budesonide aqueous spray 256 microgram (mcg)/day for treatment of rhinitis symptoms during times of high airborne pollution.

Details

Lead sponsor	Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Phase	PHASE4
Status	COMPLETED
Enrolment	206
Start date	Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Rhinitis

Interventions

• Budesonide
• Placebo

Countries

China